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MATTERS
ARISING
Long term anticoagulant
treatment in the anti-
phospholipid syndrome
The interesting paper recently published by
Derksen et al in the Annals' on the need for a
long term anticoagulant treatment in patients
with antiphospholipid antibodies and venous
thrombosis prompts several observations.
(a) Four of the 19 patients had venous
thromboembolic episodes during pregnancy
or in the immediate postpartum period. To
make their conclusion more valid, could the
authors specify if pregnancy-associated
events were initial or recurrent thrombosis?
Oral anticoagulants cannot be used at that
time, where the risk of thrombosis is
obviously high, so pregnancy-associated
thrombosis should probably be excluded
from analysis. This also applies to the study
by Rosove et al, which included three
subsequent thromboses occurring during
pregnancy or post-partum.2
(b) An oestrogen containing pill was used by
10 ofthe 19 patients at the time of 11/34 venous
thromboembolic episodes. It is not clear if the
pill was stopped after the initial episode, as
recommended by most authors.3 If it was not,
the risk of recurrent thrombosis was over-
estimated in patients still receiving the pill.
(c) For clinicians, the problem is to avoid
recurrent thrombotic events, irrespective of
their site, venous or arterial. In the study by
Derksen et al, myocardial infarction occurred
in two patients despite 'adequate' anti-
coagulation, which demonstrates that the
vascular protection provided by anti-
coagulants is not absolute.
(d) During the past years, growing evidence
has emerged favouring the long or even very
long term use of anticoagulants in patients
with antiphospholipid syndrome. A major
problem is to determine the duration of this
treatment, since it is recognised as carrying a
serious risk especially at an international
normalised ratio of three or more.' 2 It is
assumed that anticoagulants are required as
long as antiphospholipid antibodies are
present.2 To test the validity of this recom-
mendation, could Derksen et al mention the
sequential determinations of antiphospho-
lipid antibodies in their patients, with and
without relapses?
At present, the prevention of recurrent
thrombotic events in the antiphospholipid
syndrome is still a matter of debate. Two retro-
spective studies favour the use of oral anti-
coagulants.' 2 Conversely, antiplatelet agents
have been said to be effective in patients with
focal cerebral ischaemia and antiphospho-
lipid antibodies.4 Prompt relapses may occur
after warfarin' or aspirin6 withdrawal. A clear
and definitive answer, if any, requires pro-
spective controlled trials such as the recently
undertaken French cooperative study com-
paring aspirin to warfarin (AWAPS).
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AUTHORS' REPLY: We read with great interest
the letter from Drs Piette and Wechsler
concerning our recent paper in the Annals on
anticoagulant treatment in patients with anti-
phospholipid antibodies and venous
thrombosis.' We wish to make the following
comments:
1) In our series four thrombotic episodes
were pregnancy related. These were initial
thrombosis in two patients (numbers 5 and 12)
and a recurrent thrombosis in patient number
6 and 10. In 10 patients low-dose oestrogen
containing pills were used at the time of
the first episode. These pills were stopped in
all but one (number 17). Our data are
insufficient to answer the question whether
patients with antiphospholipid antibodies are
more at risk for thrombosis in the presence
of other risk factors (such as oestrogen-
containing pills, pregnancy, immobilisation,
cigarette smoking or hypercholesterolemia).
However, our observation that additional
risk factors were absent in 17/34 venous
thromboses and in at least one of the episodes
in 10/12 patients with recurrent thrombosis
indicates that antiphospholipid antibodies
itself are a risk factor, and argues against
the universal need for a 'second hit' for
thrombosis to occur.
2) Myocardial infarction that occurred in two
patients during treatment with oral anti-
coagulants suggests that this therapy does not
prevent arterial thrombosis in all patients. In
both patients we added low-dose aspirin to
treatment with oral anticoagulants.
3) Our patients were re-tested at least every
six months and all but one remained positive.
The exception was patient number 4. He
became negative for antiphospholipid anti-
bodies six months before myocardial
infarction and is still negative two years later.
This suggests that disappearance of anti-
phospholipid antibodies (defined as lupus
anticoagulants and anticardiolipin anti-
bodies) does not imply disappearance of the
risk for thrombosis, and agrees with data
showing that antibodies causing positive tests
for antiphospholipid antibodies may differ
from those causing thrombosis.2
We agree that the optimal therapy for
patients with the antiphospholipid syndrome
still has to be established. All clinical data
that have been previously reported may suffer
from selection bias. We need data from
prospective trials on unselected patients and
adequate control groups. Such trials should
stratify for any other underlying disease, type
and titre of antiphospholipid antibodies,
other risk factors for thrombosis, and type
of initial event. Due to the large number of
patients required and the expected rate of
(re-)thrombosis they should be multicentre
and have many years of follow up. Such
treatment trials are complex, expensive and
in the end probably easy to combat.
Furthermore, in each trial only a limited
number of the many possible strategies for
prophylactic treatment in patients with the
antiphospholipid syndrome can be tested.
We very much applaud the initiatives taken
by our French colleagues collaborating in
AWAPS and hope that their study will result
in a safe and effective therapy of patients with
antiphospholipid syndrome. In the mean-
time, we advise long-term treatment with oral
anticoagulants in all patients with anti-
phospholipid antibodies and venous throm-
bosis because these patients have a very high
risk of recurrent venous thrombosis, and oral
anticoagulants in contrast to acetyl salicylic
acid, effectively prevent the recurrence of
venous thrombosis.
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Evaluating new physical
treatments
I am grateful for the opportunity to respond
to your Leader article Evaluating new physical
treatments. '
Let me start by describing myself as one of
the author's electrotherapy "cynics", being
extremely sceptical of claims made for these
modalities and rarely use them. However, as
this is a controversial area of research, results
are required from a series of well designed,
controlled trials, such as the excellent study
by Heussler et al,2 so that a measured
judgement on the efficacy of the treatment
can be taken. Pre-empting these studies and
making inferences from results of a single
study would be unscientific. Moreover,
electrotherapy modalities are usually
performed as an adjunct to treatments that
aim to increase strength and range of
movement, and here their production of
"analgesia through a powerful placebo
effect"2 may be extremely useful.
It is somewhat strange that the author
readily advocates massage by manipulators
and nurses, even though massage is poorly
evaluated. Furthermore, citation of the trial
claiming chiropractic was superior to
physiotherapy in the treatment of low back
pain,3 demonstrates the danger of attaching
too great a significance to results of isolated
trials. Critical assessment of the chiropractic
study's design, execution and data analysis
suggests it was seriously flawed, and its
exaggerated and misleading conclusions have
been widely challenged.4" It therefore seems
unwise for the author to suggest NHS
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purchasers might consider "buying"
inadequately evaluated therapies, on the
same basis that physiotherapy was derided for
accepting electrotherapy by ".... giving
credence to unscientific hype". ' Caveat
emptor.
I fully endorse the author's call for more
research into the efficacy of physiotherapy,
and already many of the obstacles that
impeded physiotherapy research are being
addressed. In a recent letter in the British
Journal of Rheumatology5 I explained that
through the creation of university depart-
ments, the expertise and career structure
exists to enable us to advance research in
physiotherapy. We are now successfully
competing for funding to critically evaluate
our treatments, so that we can deliver the
most effective treatment to our patients with
the optimal use of resources.
MICHAEL V HURLEY
Physiotherapy Group
King's College
London
United Kingdom
1 Haslock I. Evaluating new physical treatments.
Ann Rheum Dis 1993; 52: 607-98.
2 Heussler J K, Hinchley G, Margiotta E, et al. A
double blind randomised trial of low power
laser treatment in rheumatoid arthritis. Ann
Rheum Dis 1993; 52: 703-6.
3 Meade T W, Dyer S, Browne W, Townsend J,
Frank A 0. Low back pain of mechanical
origin: randomised comparison of
chiropractic and hospital outpatient
treatment. BMJ 1990; 300: 1431-7.
4 Correspondence (9 letters). Low back pain:
comparison of chiropractic and hospital
outpatient treatment. BMJ7 1990; 300:
1647-50.
5 Wells P E. Manipulative treatment of the spine.
Brit_ Rheum 1993; 32: 179-80.
6 Sweetman B J. Hospital treatment for low back
pain (Letter). BritJ Rheum 1993; 32: 854.
7 Hurley M V. The way forward for hydrotherapy
(Letter). BritJ Rheum 1994; 30: 102.
AUTHOR'S REPLY: I am delighted that Dr
Hurley agrees with me that much physio-
therapy requires proper evaluation. This does
not, however, imply repeating experiments
indefinitely until the answer the researcher
wishes has been obtained. One well con-
ducted piece of research may well be all that
is necessary to answer a question, and at the
very least it requires an equally scientific reply
rather than prejudice hidden behind words
such as "measured judgments".
Had Dr Hurley read my editorial carefully
he would have realised that I nowhere
advocated the use of massage. He must
accept, though, that massage and other
complementary therapies are already high on
the list of purchasers' wishes. A recent survey
by the National Association of Health
Authorities and Trusts showed that 65% of
District Health Authorities and 70% of
Family Health Services Authorities favoured
purchasing such therapies as part of their
NHS provision.' Probably many of them act
only by a placebo effect, but few are likely to
be purchased if they advocate, as Dr Hurley
does for physiotherapy, the use of complex
pieces of electrical equipment such as lasers
as placebos.
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Distinction between
initiation and progression
ofthe osteoarthritis
process
I read with positive interest but negative
feelings the article by Cumming et al.'
Their conclusion that osteoarthritis of the
hip should be included in the list of factors
that protect against hip fracture, is in line
with our previous observation on the inverse
relationship between osteoarthritis and
osteoporosis,2 3 and in particular with the
recent epidemiological evidence revealed in
the MEDOS Study.4 The MEDOS study
is also based on self-reported osteoarthritis
in a large series of controls and hip fracture
cases. In both studies the inverse relation-
ship between osteoarthritis and osteoporosis
is independent of body weight, which
supports the hypothesis that there is a direct
causal relationship between osteoporosis and
osteoarthritis.
A disturbing element in the paper by
Cumming and Klineberg is the confusing
terminology used throughout the paper. The
term 'arthritis' is used interchangeably with
'osteoarthritis'. We do not agree that this
interchangeable terminology should be used
in an international rheumatology journal.
The term arthritis is so bound to many other
forms of arthritis, in particular rheumatoid
arthritis, gout and pelvispondylitis, that this
will inevitably lead to confusion in later
citations. Although the term osteoarthritis is
also not the best one, this term is now well
accepted as an alternative to osteoarthrosis.
According to our opinion and to many
others, such as, Radin,5 clear distinction
should be made between initiation of the
osteoarthritis process and progression. That
secondary inflammation might be involved in
the progression of osteoarthrosis is well
accepted, but whether inflammation is the
primary trigger of osteoarthritis is doubtful.
A number of studies on the initiation of the
osteoarthrosis process support the possibility
that the increased bone density reduces the
mechanical ability of subchondral bone to
deform under impact loads with resulting
damage to the articular cartilage and
osteoarthritis.6 7
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AuTHoRs' REPLY: We regret that the use
of the terms 'arthritis' and 'osteoarthritis'
appear to have been used interchangeably
in our recent paper. We can assure Drs
Dequeker and Westhovens that we gave
careful thought to the use of these two terms.
We tried to use the term 'osteoarthritis'
whenever possible (particularly in the
Introduction and Discussion sections of our
paper). However, our data were based on
self-reported joint symptoms; we did not ask
subjects about osteoarthritis specifically.
Thus we tried to use the term 'arthritis'
whenever we were referring to the data from
our study (particularly in the Results section
and in the tables). We thought it would be
misleading to readers if, for example, we
wrote about 'self-reported osteoarthritis of
the hip'.
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